SHR-4298
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 13, 2026
SHR-4298-101: A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=200 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1